US Bancorp DE Acquires 4,232 Shares of Evolent Health, Inc. (NYSE:EVH)

US Bancorp DE lifted its holdings in Evolent Health, Inc. (NYSE:EVH) by 180.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 6,579 shares of the technology company’s stock after purchasing an additional 4,232 shares during the quarter. US Bancorp DE’s holdings in Evolent Health were worth $186,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in EVH. Principal Financial Group Inc. raised its stake in shares of Evolent Health by 3.2% in the second quarter. Principal Financial Group Inc. now owns 15,594 shares of the technology company’s stock worth $298,000 after acquiring an additional 480 shares during the last quarter. Ascent Group LLC raised its position in shares of Evolent Health by 2.8% during the 1st quarter. Ascent Group LLC now owns 20,330 shares of the technology company’s stock valued at $667,000 after acquiring an additional 550 shares during the last quarter. SeaCrest Wealth Management LLC raised its position in shares of Evolent Health by 6.3% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 10,200 shares of the technology company’s stock valued at $195,000 after acquiring an additional 600 shares during the last quarter. American International Group Inc. lifted its stake in shares of Evolent Health by 1.2% in the 1st quarter. American International Group Inc. now owns 55,402 shares of the technology company’s stock valued at $1,817,000 after purchasing an additional 640 shares during the period. Finally, Arizona State Retirement System boosted its position in shares of Evolent Health by 2.3% in the 2nd quarter. Arizona State Retirement System now owns 29,083 shares of the technology company’s stock worth $556,000 after purchasing an additional 649 shares during the last quarter.

Insiders Place Their Bets

In other news, General Counsel Jonathan Weinberg sold 42,140 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $31.20, for a total value of $1,314,768.00. Following the sale, the general counsel now owns 167,027 shares of the company’s stock, valued at $5,211,242.40. The trade was a 20.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Seth Blackley sold 187,904 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total transaction of $5,637,120.00. Following the completion of the transaction, the chief executive officer now directly owns 411,924 shares of the company’s stock, valued at approximately $12,357,720. This trade represents a 31.33 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 307,291 shares of company stock worth $9,290,385. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

EVH has been the subject of a number of recent analyst reports. Oppenheimer dropped their price objective on Evolent Health from $45.00 to $34.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $20.00 price target on shares of Evolent Health in a research note on Tuesday. KeyCorp initiated coverage on shares of Evolent Health in a research note on Friday, October 11th. They set an “overweight” rating and a $35.00 price objective on the stock. JMP Securities cut their target price on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Finally, Stephens cut shares of Evolent Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $38.00 to $16.00 in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Evolent Health presently has a consensus rating of “Buy” and a consensus target price of $29.50.

Evolent Health Stock Down 0.6 %

Shares of EVH stock opened at $12.67 on Friday. Evolent Health, Inc. has a 12-month low of $12.31 and a 12-month high of $35.00. The company has a quick ratio of 1.08, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The firm has a fifty day moving average of $25.47 and a 200-day moving average of $24.45. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -13.92 and a beta of 1.58.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.